Ardelyx (BMV:ARDX *) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

ARDX * Overzicht aandelen

A biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally.

Over het bedrijf

ARDX * fundamentele analyse
Sneeuwvlok Score
Waardering	4/6
Toekomstige groei	6/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

Verhandeld tegen 87.5% onder onze schatting van de reële waarde

De winst zal naar verwachting met 65.92% per jaar groeien

Risicoanalyse

Aandelen zijn zeer illiquide

Aanzienlijke insider-verkoop in de afgelopen 3 maanden

Aandeelhouders zijn het afgelopen jaar verwaterd

Ardelyx, Inc. Concurrenten

Mabwell (Shanghai) Bioscience

SHSE:688062

CN¥10.0b

Beam Therapeutics

NasdaqGS:BEAM

US$1.9b

Ascentage Pharma Group International

SEHK:6855

HK$14.8b

Mirum Pharmaceuticals

NasdaqGM:MIRM

US$1.9b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Ardelyx
Historische aandelenkoersen
Huidige aandelenkoers	US$110.00
52 Week Hoogtepunt	US$140.00
52 Week Laag	US$63.70
Bèta	0.89
11 maand verandering	0%
3 maanden verandering	n/a
1 Jaar Verandering	n/a
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	36.99%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	ARDX *	MX Biotechs	MX Markt
7D	0%	0%	0%
1Y	n/a	0%	0%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe ARDX * presteerde ten opzichte van de MX Biotechs.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe ARDX * presteerde ten opzichte van de MX markt.

Prijsvolatiliteit

Is ARDX *'s price volatile compared to industry and market?
ARDX * volatility
ARDX * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stabiele aandelenkoers: ARDX * heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van ARDX * in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2007	267	Mike Raab	www.ardelyx.com

Ardelyx, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Ardelyx zich tot de beurswaarde?
ARDX * fundamentele statistieken
Marktkapitalisatie	Mex$27.62b
Inkomsten(TTM)	-Mex$1.24b
Inkomsten(TTM)	Mex$4.01b

6.9x

P/S-verhouding

-22.2x

Koers/Winstverhouding

Is ARDX * overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ARDX * resultatenrekening (TTM)
Inkomsten	US$210.00m
Kosten van inkomsten	US$70.84m
Brutowinst	US$139.16m
Overige uitgaven	US$204.31m
Inkomsten	-US$65.14m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.28
Brutomarge	66.27%
Nettowinstmarge	-31.02%
Schuld/Eigen Vermogen Verhouding	83.9%

Hoe presteerde ARDX * op de lange termijn?

Bekijk historische prestaties en vergelijking

ARDX * Overzicht aandelen

Beloningen

Risicoanalyse

Ardelyx, Inc. Concurrenten

SHSE:688062

CN¥10.0b

NasdaqGS:BEAM

US$1.9b

SEHK:6855

HK$14.8b

NasdaqGM:MIRM

US$1.9b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Ardelyx, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Ardelyx, Inc. to Present Additional Data Supporting First-In-Class XPHOZAH (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology's Kidney Week

Ardelyx, Inc. Announces Publication of A Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology

Robbins LLP Informs Ardelyx, Inc. Stockholders of the Class Action

Robbins LLP Informs Ardelyx, Inc. Stockholders of the Class Action

Ardelyx, Inc. Appoints Eric Foster as Chief Commercial Officer

Recent updates

Ardelyx, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Ardelyx, Inc. to Present Additional Data Supporting First-In-Class XPHOZAH (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology's Kidney Week

Ardelyx, Inc. Announces Publication of A Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology

Robbins LLP Informs Ardelyx, Inc. Stockholders of the Class Action

Robbins LLP Informs Ardelyx, Inc. Stockholders of the Class Action

Ardelyx, Inc. Appoints Eric Foster as Chief Commercial Officer

Ardelyx, Inc. Announces Publication of Two Plain Language Summaries from XPHOZAH®? (tenapanor) Clinical Trials in Current Medical Research and Opinion

Ardelyx, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Forecast breakeven date pushed back to 2026

Ardelyx, Inc.(NasdaqGM:ARDX) dropped from Russell Small Cap Comp Value Index

Ardelyx, Inc. Chooses Not to File for TDAPA to Preserve Patient Access to XPHOZAH

Insufficient new directors

Ardelyx, Inc. Announces Rodriguez Would Resign as Chief Commercial Officer

Ardelyx, Inc., Annual General Meeting, Jun 14, 2024

Ardelyx, Inc. to Report Q1, 2024 Results on May 02, 2024

Insufficient new directors

Ardelyx, Inc. Announces the Appointment of Mike Kelliher as Executive Vice President, Corporate Development and Strategy

Ardelyx, Inc. announced that it has received $50 million in funding

Ardelyx, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Insufficient new directors

Ardelyx Announces Departure of Geoffrey Block as Board Member

Ardelyx Announces Departure of Geoffrey Block as Board Member

Ardelyx, Inc. Announces XPHOZAH(R) (tenapanor) Now Available in the United States

Ardelyx Shares Positive Data from Studies of Xphozah®? (Tenapanor) At Asn Kidney Week 2023

New major risk - Shareholder dilution

Ardelyx, Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$0.03 (vs US$0.14 loss in 3Q 2022)

Ardelyx, Inc. to Report Q3, 2023 Results on Oct 31, 2023

Insufficient new directors

Ardelyx, Inc. Shares Positive Data on Symptom Response During Treatment with IBSRELA®? (tenapanor) for IBS-C and Hosts IBS-C Product Theater at ACG 2023

Ardelyx, Inc. Announces FDA Approval of XPHOZAH (tenapanor), a First-In-Class Phosphate Absorption Inhibitor

Ardelyx, Inc. Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility

New major risk - Shareholder dilution

First quarter 2023 earnings released: US$0.13 loss per share (vs US$0.21 loss in 1Q 2022)

Forecast breakeven date pushed back to 2025

Ardelyx, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Forecast breakeven date pushed back to 2025

Ardelyx, Inc. Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH(R)

First quarter 2023 earnings released: US$0.13 loss per share (vs US$0.21 loss in 1Q 2022)

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Ardelyx, Inc. Samenvatting

6.9x

-22.2x

Inkomsten en omzet